Obsidian Therapeutics Secures $160.5 Million in Series C Funding for Revolutionary Cell and Gene Therapies

Obsidian Therapeutics has successfully raised an impressive $160,500,000 in funding. The company, known for pioneering controllable cell and gene therapies to revolutionize treatment outcomes for patients with challenging diseases, plans to utilize the funds to further advance their innovative programs. Obsidian’s cutting-edge cytoDriveTM technology is designed to regulate the expression of proteins in cell and gene therapy products, enhancing their therapeutic effectiveness. Their lead program, cytoTIL15, aims to boost the efficacy of TILs for a larger number of patients. Backed by a team of experienced professionals, industry leaders, and esteemed investors, Obsidian Therapeutics is driven by a mission to develop transformative therapies for critical clinical needs. Situated in Cambridge with a newly established laboratory in Bedford, the company prides itself on its diverse and talented workforce and is committed to fostering an inclusive environment where every team member can flourish. Competitive salaries, benefits, and opportunities for employee ownership through stock options further enhance Obsidian’s dedication to supporting its employees.